Patent · US Active

Compounds

US9815841B2 · kind B2 · utility

2Cited by

5References

13Claims

0Family size

Assignee

GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

Xiao Ding · Chesterfield, US
Qian Liu · Suzhou, CN
Kai Long · Shanghai, CN
Yingxia Sang · Shanghai, CN
Luigi Piero Stasi · Verona, IT
Zehong Wan · King of Prussia, US
Qiongfeng Xu · Shanghai, CN
Colin Michael Edge · Shanghai, CN

Key dates

Filing date	Jan 28, 2015
Grant date	Nov 14, 2017
Priority date	—
Expiry date	Jan 28, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.